CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- The Lancet. Oncology
- Publicado em
- 1 mai 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Mohammed S Beshr, Ammar Fahaid, Rana H Shembesh, Antonios Valachis, Matteo Lambertini, Laura Cortesi, Alzahraa Faris Alesawy, Ahmed Abraheem, Mohamed Alsharedi, Mohamed E Ali et al.
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Purines
- Progression-Free Survival
- Receptors, Estrogen
- Receptors, Progesterone